Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02305563 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02305563 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT02305563, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).
Interventions
- DRUG Cytarabine
- DRUG BMS-936564
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-01-27 |
| Est. Completion | 2019-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02305563
The ClinicalTrials.gov registry entry for NCT02305563 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT02305563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02305563 about?
NCT02305563 is a clinical study titled "An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia". The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).
What is the current status of trial NCT02305563?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-01-27. Estimated completion is 2019-06-04.
What interventions are being tested in trial NCT02305563?
The interventions under investigation include: Cytarabine (DRUG), BMS-936564 (DRUG).
Who is sponsoring clinical trial NCT02305563?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.